Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

Abstract Background Anlotinib significantly extended progression‐free survival (PFS) and overall survival (OS) in small‐cell lung cancer (SCLC) as third or later line treatment. Methods In this study, we retrospectively analyzed the efficacy and safety of anlotinib in the clinical practice and aimed...

Full description

Bibliographic Details
Main Authors: Boyu Qin, Lingli Xin, Qingxiang Hou, Bo Yang, Jing Zhang, Xiaoguang Qi, Yingtian Wei, Yi Hu, Qi Xiong
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Cancer Medicine
Subjects:
anlotinib
efficacy
independent risk factor
small‐cell lung cancer
Online Access:https://doi.org/10.1002/cam4.3941

Internet

https://doi.org/10.1002/cam4.3941

Similar Items